OvaScience Inc. (NASDAQ:OVAS) has earned a consensus rating of “Hold” from the eight brokerages that are presently covering the firm. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $9.17.
OVAS has been the subject of several research analyst reports. Credit Suisse Group AG reissued a “sell” rating on shares of OvaScience in a research note on Tuesday, July 12th. Zacks Investment Research raised OvaScience from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research note on Wednesday, August 10th. JMP Securities reissued a “neutral” rating on shares of OvaScience in a research note on Wednesday, August 10th. Finally, JPMorgan Chase & Co. dropped their price objective on OvaScience from $9.00 to $8.00 and set a “neutral” rating for the company in a research note on Friday, August 5th.
Shares of OvaScience (NASDAQ:OVAS) opened at 6.32 on Thursday. The company’s 50 day moving average price is $7.08 and its 200 day moving average price is $7.06. The company’s market cap is $224.75 million. OvaScience has a 12 month low of $4.53 and a 12 month high of $15.39.
OvaScience (NASDAQ:OVAS) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.16. The company earned $0.19 million during the quarter, compared to analyst estimates of $0.21 million. OvaScience had a negative return on equity of 60.10% and a negative net margin of 13,906.35%. The firm’s quarterly revenue was up 530.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.64) earnings per share. On average, equities analysts expect that OvaScience will post ($2.66) EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors increased its position in OvaScience by 31.8% in the second quarter. Nationwide Fund Advisors now owns 20,068 shares of the company’s stock valued at $105,000 after buying an additional 4,846 shares in the last quarter. Citadel Advisors LLC bought a new position in OvaScience during the second quarter valued at approximately $122,000. ProShare Advisors LLC increased its position in OvaScience by 28.7% in the second quarter. ProShare Advisors LLC now owns 29,507 shares of the company’s stock valued at $154,000 after buying an additional 6,572 shares in the last quarter. Northern Capital Management LLC increased its position in OvaScience by 61.0% in the second quarter. Northern Capital Management LLC now owns 30,340 shares of the company’s stock valued at $158,000 after buying an additional 11,500 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC bought a new position in OvaScience during the second quarter valued at approximately $164,000. Institutional investors and hedge funds own 80.70% of the company’s stock.
OvaScience Company Profile
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.